阿尔波特综合征
医学
无症状的
异常
泌尿系统
复合杂合度
内科学
等位基因
发病年龄
杂合子优势
胃肠病学
肾小球肾炎
疾病
病理
遗传学
肾
生物
基因
精神科
作者
Tomoko Horinouchi,Tomohiko Yamamura,China Nagano,Nana Sakakibara,Shinya Ishiko,Yuya Aoto,Rini Rossanti,Koichi Nakanishi,Yuko Shima,Naoya Morisada,Kazumoto Iijima,Kandai Nozu
出处
期刊:Kidney360
[American Society of Nephrology (ASN)]
日期:2020-07-17
卷期号:1 (9): 936-942
被引量:5
标识
DOI:10.34067/kid.0000372019
摘要
Autosomal recessive Alport syndrome (ARAS) is an inherited renal disorder caused by homozygous and compound heterozygous mutations in COL4A3 or COL4A4, but the prognostic predictors for this disorder are not yet fully understood. Recently, the magnitude of the clinical spectrum of the COL4A3 and COL4A4 heterozygous state has attracted attention. This spectrum includes asymptomatic carriers of ARAS, benign familial hematuria, thin basement membrane disease, and autosomal dominant Alport syndrome.We retrospectively analyzed 49 patients with ARAS from 41 families with a median age of 19 years to examine the clinical features and prognostic factors of ARAS, including the associated genotypes.The median age of patients with ARAS at ESKD onset was 27 years. There was no significant association between the presence or absence of hearing loss or truncating mutations and renal prognosis. However, there was a statistically significant correlation between renal prognosis and heterozygous variants that cause urinary abnormalities. Where the urinary abnormality-causing variant was absent or present in only one allele, the median age of ESKD onset was 45 years, whereas the same variant present on both alleles was associated with an age of onset of 15 years (P<0.001).This study was the first to demonstrate the clinical importance in ARAS of focusing on variants in COL4A3 or COL4A4 that cause urinary abnormalities in both the homozygous or heterozygous state. Although heterozygous mutation carriers of COL4A3 and COL4A4 comprise a broad clinical spectrum, clinical information regarding each variant is important for predicting ARAS prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI